Navigating Clinical Trials: Essential Knowledge for Dermatologists-Alopecia Areata Clinical Trials: Tips and Tricks

Video Transcription

Video Summary

David Rosemary, Chair of Dermatology at Indiana University, discusses clinical trials for alopecia areata, focusing on endpoints, placebo rates, and inclusion-exclusion criteria. Trials range from Phase 1, assessing safety, to Phase 3, essential for regulatory approval. Key measures include the SALT score to evaluate hair loss. Study design should consider trial duration, placebos, and patient response duration after treatment stops. Inclusion criteria should account for severity, patient history, and comorbidities. The partnership with patients, safety, and understanding individual needs are crucial. The future may involve biomarkers and new treatments, especially JAK inhibitors and potential topicals.

Asset Subtitle

by David Rosmarin, MD, FAAD

Meta Tag

Concept Phase 1 Study

Concept Clinical Trial Phase II

Concept Phase III Clinical Trial

Concept Efficacy

Concept Alopecia Areata

Concept SALT Score

Concept SALT 20 Endpoint

Keywords

alopecia areata

clinical trials

SALT score

JAK inhibitors

biomarkers

Phase 1 Study

Clinical Trial Phase II

Phase III Clinical Trial

Efficacy

Alopecia Areata

SALT Score

SALT 20 Endpoint